SBRT治疗PSMA PET检出的寡转移性前列腺癌的长期结局
该回顾性单中心研究分析了103例接受PSMA-PET引导下SBRT且未初始使用ADT的寡转移性前列腺癌患者,中位随访5年。5年无任何生化失败率为15%,中位至生化失败时间1.1年;5年39%患者从未接受ADT,55%未因复发启动ADT,中位至复发ADT时间5.5年。2例3级毒性,无局部失败。
要点
- PSMA-PET引导SBRT后5年无任何生化失败率15%,中位至生化失败1.1年。
- 5年39%从未接受ADT,55%未因复发启动ADT,中位至复发ADT时间5.5年。
- 2例3级毒性(肋骨骨折和淋巴水肿),无局部失败。
核心结论
- 对经过适当分流的寡转移性前列腺癌复发患者,PSMA-PET引导SBRT可获得极好的局部控制、低毒性,5年时超过50%无ADT生存。
研究设计与样本
- 回顾性单中心研究,分析2014年11月至2019年12月治疗的103例PSMA-PET引导SBRT且未初始使用ADT的寡转移性前列腺癌患者。
- 骨转移中位剂量/分次为24 Gy/2次,淋巴结转移为30 Gy/3次。
- 主要终点为至生化失败时间(PSA较最低值升高+0.2 ug/L);次要终点包括至因复发启动ADT(即姑息性ADT)时间、生化失败(定义为PSA最低值+2 ug/L)、毒性、失败模式和生存。
- 排除接受SBRT时同时使用ADT、无病间期短或PSMA-PET显示>3个转移灶的患者。
主要发现
- 中位随访5年;64例仅淋巴结转移,35例仅骨转移,4例混合转移。
- 5年时15%患者无任何生化失败,中位至生化失败时间1.1年。
- 32%(33/103)患者在SBRT后首次生化失败后接受了进一步根治性放疗,包括后续SBRT;8例患者因第二或第三次复发接受了潜在根治性治疗。
- 允许挽救治疗后,29/103(28%)患者在末次随访时生化无病。
- 5年时39%患者从未接受任何ADT,55%未因复发启动ADT,中位至复发ADT时间5.5年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oligometastatic disease in prostate cancer (PCa) is a challenging clinical scenario encountered more frequently with the widespread adoption of PSMA-PET. SBRT aims to defer androgen deprivation and may deliver sustained biochemical failure (BF) free survival in selected patients. Little long-term data is currently available regarding the effectiveness of this approach. METHODS: A retrospective single institution study of PSMA-PET directed SBRT without initial ADT for oligo-metachronous PCa. Median dose/fractionation was 24 Gy in 2# to bones and 30 Gy in 3# to lymph nodes. The primary endpoint was time to BF (PSA + 0.2 ug/L above nadir). Secondary endpoints included time to ADT for relapse (i.e. palliative ADT), BF defined as PSA nadir + 2 ug/L, toxicity, patterns of failure and survival. Patients were excluded if they received ADT with their SBRT, had short disease-free interval, or > 3 metastases on PSMA-PET. RESULTS: 103 patients treated from November-2014 to December-2019 were analysed from our prospective database. Median follow-up was 5 years. 64 patients were treated for nodal only disease, 35 bone only and 4 mixed. 15% were free of any BF at 5 years with median time to BF of 1.1 years. 32% (33/103) of patients had further curative-intent radiation treatment following their first BF after SBRT, including subsequent SBRT. Eight patients underwent potentially curative treatment for their second or third relapse. Allowing for salvage treatment, 29/103 (28%) were biochemically disease free at last follow up. At 5 years, 39% of patients had never received any ADT and 55% had not started ADT for relapse with a median time to ADT for relapse of 5.5 years. There were 2 grade 3 toxicities (rib fracture and lymphoedema), and no local failures. CONCLUSION: PSMA-PET guided SBRT for oligo-metachronous PCa recurrence in appropriately triaged patients results in excellent local control, low toxicity and over 50% ADT free at 5 years.
引用
- Mohan R, Kneebone A, Eade T, et al. Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer. Radiat Oncol. 2023. PMID: 37528487. doi:10.1186/s13014-023-02302-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。